AstraZeneca’s Fasenra Approved for Rare Blood Disorder in India
By ThePip Desk
AstraZeneca India’s Fasenra (Benralizumab) receives CDSCO approval for hypereosinophilic syndrome (HES) in patients 12+, marking a significant expansion for the rare disease treatment.
🔥 Main Takeaway: AstraZeneca Pharma India just scored a major regulatory win, securing approval for its drug Fasenra to treat a rare blood disorder, potentially opening up a new revenue stream.
📌 What Happened?
The Central Drugs Control Organization (CDSCO) has greenlit Benralizumab, known as Fasenra, for an additional indication in India.
This approval allows AstraZeneca Pharma India to import and market the 30 mg/ml solution for injection in a pre-filled syringe.
Fasenra is now approved to treat hypereosinophilic syndrome (HES) in patients aged 12 years and above, specifically those without an identifiable non-haematologic secondary cause.
This regulatory clearance expands Fasenra’s reach in India, pending any further statutory approvals.
Looking at the financials for the quarter ending March 2026, AstraZeneca Pharma India reported a 22.95% decline in standalone net profit to Rs 44.88 crore, even as sales surged by 20.42% to Rs 578.61 crore.
💰 Why It Matters
For investors, this new indication for Fasenra unlocks a niche but significant market in the rare diseases segment, which could boost future revenue growth.
The approval signals a strategic expansion into specialized treatments within India’s pharmaceutical landscape, aligning with global trends towards targeted therapies.
Despite a dip in net profit, the substantial 20.42% rise in sales suggests robust underlying demand for AstraZeneca’s existing portfolio, with Fasenra’s expanded use poised to contribute further.
From a healthcare perspective, this provides a much-needed new treatment option for HES patients aged 12 and above in India.
👀 What to Watch Next
Keep an eye on Fasenra’s sales performance specifically within the HES treatment area to gauge its market penetration and revenue contribution.
Look for further updates on additional statutory approvals or new marketing strategies AstraZeneca Pharma India might deploy to capitalize on this expanded indication.
Monitor how this new revenue stream impacts the company’s overall financial health and profit margins in the upcoming quarters, especially given the recent profit decline.